- Home
- WULF vs RNA Comparison
WULF vs RNA Comparison
Compare WULF & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WULF
- RNA
- Stock Information
- Founded
- WULF 1952
- RNA 2012
- Country
- WULF United States
- RNA United States
- Employees
- WULF N/A
- RNA N/A
- Industry
- WULF EDP Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- WULF Technology
- RNA Health Care
- Exchange
- WULF Nasdaq
- RNA Nasdaq
- Market Cap
- WULF 4.5B
- RNA 4.0B
- IPO Year
- WULF 1995
- RNA 2020
- Fundamental
- Price
- WULF $14.83
- RNA $71.58
- Analyst Decision
- WULF Strong Buy
- RNA Buy
- Analyst Count
- WULF 12
- RNA 20
- Target Price
- WULF $16.71
- RNA $69.26
- AVG Volume (30 Days)
- WULF 48.9M
- RNA 4.9M
- Earning Date
- WULF 11-10-2025
- RNA 11-10-2025
- Dividend Yield
- WULF N/A
- RNA N/A
- EPS Growth
- WULF N/A
- RNA N/A
- EPS
- WULF N/A
- RNA N/A
- Revenue
- WULF $167,604,000.00
- RNA $20,868,000.00
- Revenue This Year
- WULF $41.01
- RNA N/A
- Revenue Next Year
- WULF $118.36
- RNA $108.97
- P/E Ratio
- WULF N/A
- RNA N/A
- Revenue Growth
- WULF 30.58
- RNA 106.27
- 52 Week Low
- WULF $2.06
- RNA $21.51
- 52 Week High
- WULF $17.05
- RNA $71.75
- Technical
- Relative Strength Index (RSI)
- WULF 59.75
- RNA 79.87
- Support Level
- WULF $10.47
- RNA $70.42
- Resistance Level
- WULF $14.75
- RNA $71.04
- Average True Range (ATR)
- WULF 1.46
- RNA 0.46
- MACD
- WULF 0.11
- RNA -0.76
- Stochastic Oscillator
- WULF 92.49
- RNA 91.11
About WULF TeraWulf Inc.
TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.